2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Benjamin H. Lowentritt, MD, FACS, discusses the real-world analysis of apalutamide and enzalutamide in metastatic castration-sensitive prostate cancer.
Benjamin H. Lowentritt, MD, FACS, director, Minimally Invasive Surgery and Robotics, director, Prostate Cancer Care Program, Chesapeake Urology, president, AUA, MidAtlantic Region, discusses the real-world analysis of apalutamide (Erleada) and enzalutamide (Xtandi) in metastatic castration-sensitive prostate cancer (mCSPC).
Conducting a real-world analysis was difficult in the past; however, researchers are finding data can be extracted from appropriate patients if they are accessible, Lowentritt says. This study provided an opportunity to examine data from a system that works in several community urology groups, Lowentritt adds.
To complete the analysis, patient data were retrieved and examined. Though this method will never duplicate what comes out of a prospective randomized trial, it provides an insight into real-world and what impacts these the treatments are having, Lowentritt continues. Work on medication adherence and some other issues led to this real-world analysis, Lowentritt concludes.